How Blow-Fill-Seal Delivers Operational Efficiencies and Aseptic Fill-Finish
Pharma expert, Joe Wojcik, discusses the technical factors and requirements that make BFS an “advanced aseptic process” for fill-finish, and why BFS has relatively low capital requirements
What Have Been the Biggest Surprises with COVID-19?
with Ed Kelley, PhD, Chief Global Health Officer
The pandemic’s effects have been far more wide-reaching than many health officials expected, but COVID has also accelerated some positive trends.
Advances in Sterile Liquids Packaging and Form Factors
with Jon Burgess, Packaging Engineer
Discussion on packaging factors that have led to wider acceptance of Blow-Fill-Seal technology in the pharmaceutical industry.
Strengths of Diversity in Pharma
with Amy Stewart, Chief People Officer
Companies are realizing that a strong commitment to DEI and ESG attracts employees. Word of mouth is very powerful. Companies want to do business with partners that are inclusive with positive values and environmental initiatives.
The Surprising Strengths of Blow-Fill-Seal
with Philip Leslie, Acting Head of Manufacturing
Why does the FDA calls BFS an “advanced aseptic process”? How does BFS combine high-speed, economically efficient production with notable manufacturing flexibility? Respected industry veteran Philip Leslie explains “the basics of BFS.”
BFS Covers Injectables and Vaccines, Too
with Ray Sell, Vice President, Business Development
BFS drug delivery systems go far beyond ophthalmic and oral solutions; BFS is also used to fill-finish injectables and vaccines.
The Heat Factor: Part 1 & 2:Why it Matters in Blow-Fill-Seal
with Jeff Price, Consulting Principal BFS Engineer
At ApiJect, our engineers have taken these filling enhancements even further by developing proprietary temperature control management methods that can potentially enable many temperature sensitive biologics and vaccines that are not possible on standard BFS lines.